Logo image of RDHL

REDHILL BIOPHARMA LTD-SP ADR (RDHL) Stock Fundamental Analysis

NASDAQ:RDHL - Nasdaq - US7574683014 - ADR - Currency: USD

1.95  -0.05 (-2.5%)

Fundamental Rating

1

Overall RDHL gets a fundamental rating of 1 out of 10. We evaluated RDHL against 195 industry peers in the Pharmaceuticals industry. RDHL may be in some trouble as it scores bad on both profitability and health. RDHL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RDHL had negative earnings in the past year.
RDHL had a negative operating cash flow in the past year.
RDHL had negative earnings in 4 of the past 5 years.
In the past 5 years RDHL always reported negative operating cash flow.
RDHL Yearly Net Income VS EBIT VS OCF VS FCFRDHL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

RDHL has a Return On Assets (-45.82%) which is in line with its industry peers.
Industry RankSector Rank
ROA -45.82%
ROE N/A
ROIC N/A
ROA(3y)4.28%
ROA(5y)-16.67%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RDHL Yearly ROA, ROE, ROICRDHL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K

1.3 Margins

RDHL's Gross Margin of 60.31% is fine compared to the rest of the industry. RDHL outperforms 69.23% of its industry peers.
RDHL's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for RDHL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.56%
GM growth 5Y-1.2%
RDHL Yearly Profit, Operating, Gross MarginsRDHL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

0

2. Health

2.1 Basic Checks

RDHL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RDHL has been increased compared to 1 year ago.
Compared to 5 years ago, RDHL has more shares outstanding
RDHL has a better debt/assets ratio than last year.
RDHL Yearly Shares OutstandingRDHL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
RDHL Yearly Total Debt VS Total AssetsRDHL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

RDHL has an Altman-Z score of -34.98. This is a bad value and indicates that RDHL is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -34.98, RDHL is not doing good in the industry: 87.69% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -34.98
ROIC/WACCN/A
WACC8.54%
RDHL Yearly LT Debt VS Equity VS FCFRDHL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

A Current Ratio of 0.54 indicates that RDHL may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.54, RDHL is doing worse than 92.82% of the companies in the same industry.
RDHL has a Quick Ratio of 0.54. This is a bad value and indicates that RDHL is not financially healthy enough and could expect problems in meeting its short term obligations.
RDHL has a Quick ratio of 0.37. This is amonst the worse of the industry: RDHL underperforms 92.82% of its industry peers.
Industry RankSector Rank
Current Ratio 0.54
Quick Ratio 0.37
RDHL Yearly Current Assets VS Current LiabilitesRDHL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for RDHL have decreased strongly by -100.30% in the last year.
RDHL shows a strong growth in Revenue. In the last year, the Revenue has grown by 23.17%.
The Revenue has been growing slightly by 5.04% on average over the past years.
EPS 1Y (TTM)-100.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100.3%
Revenue 1Y (TTM)23.17%
Revenue growth 3Y-54.57%
Revenue growth 5Y5.04%
Sales Q2Q%23.17%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to grow by 45.22% on average over the next years. This is a very strong growth
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year82.69%
Revenue Next 2Y55.97%
Revenue Next 3Y45.22%
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RDHL Yearly Revenue VS EstimatesRDHL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
RDHL Yearly EPS VS EstimatesRDHL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 -500 -1K -1.5K -2K -2.5K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RDHL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RDHL Price Earnings VS Forward Price EarningsRDHL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RDHL Per share dataRDHL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

RDHL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REDHILL BIOPHARMA LTD-SP ADR

NASDAQ:RDHL (6/12/2025, 9:45:23 AM)

1.95

-0.05 (-2.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-16 2024-09-16
Earnings (Next)N/A N/A
Inst Owners6.77%
Inst Owner Change112.7%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.47M
Analysts82.86
Price Target19380 (993746.15%)
Short Float %2064.77%
Short Ratio0.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.56
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.76
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-4.09
FCFYN/A
OCF(TTM)-4.09
OCFYN/A
SpS3.51
BVpS-2.04
TBVpS-4.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.31%
FCFM N/A
ROA(3y)4.28%
ROA(5y)-16.67%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.56%
GM growth 5Y-1.2%
F-Score3
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.45%
Cap/Sales 0.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.54
Quick Ratio 0.37
Altman-Z -34.98
F-Score3
WACC8.54%
ROIC/WACCN/A
Cap/Depr(3y)1.49%
Cap/Depr(5y)123.93%
Cap/Sales(3y)0.2%
Cap/Sales(5y)16.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-100.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100.3%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)23.17%
Revenue growth 3Y-54.57%
Revenue growth 5Y5.04%
Sales Q2Q%23.17%
Revenue Next Year82.69%
Revenue Next 2Y55.97%
Revenue Next 3Y45.22%
Revenue Next 5YN/A
EBIT growth 1Y-215.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y73.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.84%
OCF growth 3YN/A
OCF growth 5YN/A